Scheduled Maintenance: Saturday, May 4th, starting at 8PM EST
We will be upgrading some systems and expect the maintenance to last no more than 2 hours. During the maintenance window, you will not have access to this portal.

NNNS: Food Intake (2006)

Citation:
 
Study Design:
Class:
- Click here for explanation of classification scheme.
Quality Rating:
Research Purpose:
To investigate the relationships between reduced energy product consumption and nutritional parameters, anthropometry and biochemical markers.
Inclusion Criteria:
  • Adults in France that participated in the SU.VI.MAX cohort: Supplemetntation of vitamins and minerals antioxidants study
  • Included in eight-year follow-up starting in 1994.
Exclusion Criteria:
If not in study.
Description of Study Protocol:

Recruitment

  • Subset of volunteers from project were randomly selected.

Design

  • Men and women, 45 to 60 years old, reported their food intakes over six non-consecutive days
  • Consumers of low-fat and low-sugar foods and drinks and artificial sweeteners were compared with non-consumers.

Intervention

  • Volunteers were ascribed to different groups depending on their food intake.
    • Non-consumers: No intake over six days of fat-reduced, sugar-reduced or alcohol reduced products.
    • Occasional users: One to three days over six days with at least one intake of fat-reduced, sugar-reduced or alcohol reduced products.
    • Regular consumers: Three to five days over six days with at least one intake of fat-reduced, sugar-reduced or alcohol reduced products.
    • High consumers: Six days with at least one intake of fat-reduced, sugar-reduced or alcohol reduced products.

Statistical Analysis

  • SAS statistical package, comparisons of means were performed by analysis of variance, adjusted for age. Data for males and females were analyzed separately.
  • Energy intake and macronutrient intake was estimated using the computerized food composition tables and compared with the French Recommended Dietary Allowances. Nutrient density was expressed as amount per 1,000kcal.
Data Collection Summary:

Timing of Measurements

  • 24-hour dietary record: Subjects record every other month, for a total of six records per year. Provided with a small processing unit with ad hoc software to fill out questionnaires. Types of foods (fresh, frozen, canned, etc.) as well as cooking methods, seasonings, place and time of intake were recorded.
  • Biochemical measurements: Obtained at the beginning of the initial visit of the study. 35ml venous blood samples were obtained after a 24-hour fast
  • Clinical examinations: Were performed one year after inclusion and included anthropometric data (height, weight, waist and hip circumferences). Data collected from October 1995 to July 1996. 
Description of Actual Data Sample:
  • Initial N12,735 women and men (2,299 men and 1,979 women, aged 35-60 years participated) 
  • Age: Women ages 35-60 years, men aged 45-60 years
  • Anthropometrics: BMI average was around 25
  • Location: Represented eight geographical regions of France.
Summary of Results:

Other Findings

  •  Among women using artificial sweeteners, one-third do not consume sucrose at all.

Low-Sugar Products

  • Low-sugar drinks and foods are rarely consumed in this population. Artificial sweeteners are used fairly frequently by 22% of men and 30% of women. Over 15% if the subjects utilize them regulary or often. Nine men (0.4%) and 371 women (19%) used both low-sugar (artificial sweeteners) and low-fat products at least occasionally.
  • Male and female users of low-sugar products were heavier, had higher BMI and waist-to-hip ratio
  • Male and female users of low-sugar products had higher triacylglycerolaemia and fasting glycemia than non-users.
  • Cholesterol values were not different
  • Male users of low-sugar products ingested less energy, less protein from vegetable origin, less carbohydrates and less sucrose than non-users. Animal protein intake was higher in high consumers of low-sugar products than in non-consumers and occasional consumers.
  • In male consumers of low-sugar foods, the proportions of protein and fat in the diet were linear and significant with frequency use, while that of carbohydrates decreased
  • In women, intake of vegetable protein, carbohydrates and sucrose decreased linearly with frequency of use of low-sugar intake of animal proteins. The proportion of proteins in the diet also increased with the use of low-sugar products, while the proportion of carbohydrates decreased.

Low-Fat Products

  • In all groups, protein and fat intake was higher than recommendataions (proteins about 12% and fat less than 35%). Carbohydrates was less.
  • Micronutrient intake: Few differences between users and non-users. No differences in absolute daily intake except cholesterol was consumed in larger amounts by users of low-sugar products.
  • Density of the diet was higher in male and female users than in non-users for Vitamis E, riboflavin, B6, niacin, cholesterol, calcium, potassium, magnesium and phospohorus
  • Use of low-fat products was associated with no anthropometric differnce in men, whereas female users were heavier than non-users. The BMI in the heaviest groups of women were below the BMI=25 defining obesity. Users and non-users had similar biochemical markers.
  • Male users of low-fat products consumed less fat and more carbohydrates than male non-users. The proportion of daily energy intake from fat was lower in high-frequency users of low-fat products. The percentages of proteins and carbohydrates in the diet increased with frequency of low-fat food intake. 
  • In women, the use of low-fat products was associated with more protein (especially animal), more sucrose and less alcohol than non-users
  • Male users of low-fat had higher micronutrient intakes (carotenoids, vitamins C, E and B2 and calcium, magnesium and phosphorus). The density of the diet in most micronutrients was higher in male users of low-fat products.
  • Daily micronutrient intake was higher in female users in both absolute and in density, except for vitamins A and D.
Author Conclusion:

In mature adults, the selection of fat-reduced products was associated with improved quality of the diet, while anthropometrics and biological parameters appeared less favorable in consumers of low-sugar products vs. non-consumers. The longitudinal follow-up of the cohoort in future years will help determine a cause-and-effect relationships among these parameters. 

Limitations

  • Unlikely massive underreporting behavior observed in the subjects who were obese create biases.
  • Differences in energy expenditures could have made some individuals more prone to weight gain and more susceptible to consume energy-reduced products in their diet.
Funding Source:
Other: no reported funding
Reviewer Comments:
Quality Criteria Checklist: Primary Research
Relevance Questions
  1. Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) Yes
  1. Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) Yes
  2. Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? Yes
  2. Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? Yes
  3. Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? Yes
  3. Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? Yes
  4. Is the intervention or procedure feasible? (NA for some epidemiological studies) Yes
  4. Is the intervention or procedure feasible? (NA for some epidemiological studies) Yes
 
Validity Questions
  1. Was the research question clearly stated? Yes
1. Was the research question clearly stated? Yes
  1.1. Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? Yes
  1.1. Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? Yes
  1.2. Was (were) the outcome(s) [dependent variable(s)] clearly indicated? Yes
  1.2. Was (were) the outcome(s) [dependent variable(s)] clearly indicated? Yes
  1.3. Were the target population and setting specified? Yes
  1.3. Were the target population and setting specified? Yes
  2. Was the selection of study subjects/patients free from bias? Yes
2. Was the selection of study subjects/patients free from bias? Yes
  2.1. Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? No
  2.1. Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? No
  2.2. Were criteria applied equally to all study groups? Yes
  2.2. Were criteria applied equally to all study groups? Yes
  2.3. Were health, demographics, and other characteristics of subjects described? No
  2.3. Were health, demographics, and other characteristics of subjects described? No
  2.4. Were the subjects/patients a representative sample of the relevant population? Yes
  2.4. Were the subjects/patients a representative sample of the relevant population? Yes
  3. Were study groups comparable? Yes
3. Were study groups comparable? Yes
  3.1. Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) Yes
  3.1. Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) Yes
  3.2. Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? No
  3.2. Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? No
  3.3. Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) No
  3.3. Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) No
  3.4. If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? Yes
  3.4. If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? Yes
  3.5. If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) N/A
  3.5. If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) N/A
  3.6. If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? N/A
  3.6. If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? N/A
  4. Was method of handling withdrawals described? Yes
4. Was method of handling withdrawals described? Yes
  4.1. Were follow-up methods described and the same for all groups? No
  4.1. Were follow-up methods described and the same for all groups? No
  4.2. Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) N/A
  4.2. Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) N/A
  4.3. Were all enrolled subjects/patients (in the original sample) accounted for? Yes
  4.3. Were all enrolled subjects/patients (in the original sample) accounted for? Yes
  4.4. Were reasons for withdrawals similar across groups? N/A
  4.4. Were reasons for withdrawals similar across groups? N/A
  4.5. If diagnostic test, was decision to perform reference test not dependent on results of test under study? N/A
  4.5. If diagnostic test, was decision to perform reference test not dependent on results of test under study? N/A
  5. Was blinding used to prevent introduction of bias? No
5. Was blinding used to prevent introduction of bias? No
  5.1. In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? N/A
  5.1. In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? N/A
  5.2. Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) Yes
  5.2. Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) Yes
  5.3. In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? No
  5.3. In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? No
  5.4. In case control study, was case definition explicit and case ascertainment not influenced by exposure status? N/A
  5.4. In case control study, was case definition explicit and case ascertainment not influenced by exposure status? N/A
  5.5. In diagnostic study, were test results blinded to patient history and other test results? N/A
  5.5. In diagnostic study, were test results blinded to patient history and other test results? N/A
  6. Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? No
6. Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? No
  6.1. In RCT or other intervention trial, were protocols described for all regimens studied? N/A
  6.1. In RCT or other intervention trial, were protocols described for all regimens studied? N/A
  6.2. In observational study, were interventions, study settings, and clinicians/provider described? N/A
  6.2. In observational study, were interventions, study settings, and clinicians/provider described? N/A
  6.3. Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? No
  6.3. Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? No
  6.4. Was the amount of exposure and, if relevant, subject/patient compliance measured? No
  6.4. Was the amount of exposure and, if relevant, subject/patient compliance measured? No
  6.5. Were co-interventions (e.g., ancillary treatments, other therapies) described? N/A
  6.5. Were co-interventions (e.g., ancillary treatments, other therapies) described? N/A
  6.6. Were extra or unplanned treatments described? N/A
  6.6. Were extra or unplanned treatments described? N/A
  6.7. Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? N/A
  6.7. Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? N/A
  6.8. In diagnostic study, were details of test administration and replication sufficient? N/A
  6.8. In diagnostic study, were details of test administration and replication sufficient? N/A
  7. Were outcomes clearly defined and the measurements valid and reliable? No
7. Were outcomes clearly defined and the measurements valid and reliable? No
  7.1. Were primary and secondary endpoints described and relevant to the question? Yes
  7.1. Were primary and secondary endpoints described and relevant to the question? Yes
  7.2. Were nutrition measures appropriate to question and outcomes of concern? No
  7.2. Were nutrition measures appropriate to question and outcomes of concern? No
  7.3. Was the period of follow-up long enough for important outcome(s) to occur? No
  7.3. Was the period of follow-up long enough for important outcome(s) to occur? No
  7.4. Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? No
  7.4. Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? No
  7.5. Was the measurement of effect at an appropriate level of precision? Yes
  7.5. Was the measurement of effect at an appropriate level of precision? Yes
  7.6. Were other factors accounted for (measured) that could affect outcomes? No
  7.6. Were other factors accounted for (measured) that could affect outcomes? No
  7.7. Were the measurements conducted consistently across groups? Yes
  7.7. Were the measurements conducted consistently across groups? Yes
  8. Was the statistical analysis appropriate for the study design and type of outcome indicators? Yes
8. Was the statistical analysis appropriate for the study design and type of outcome indicators? Yes
  8.1. Were statistical analyses adequately described and the results reported appropriately? Yes
  8.1. Were statistical analyses adequately described and the results reported appropriately? Yes
  8.2. Were correct statistical tests used and assumptions of test not violated? Yes
  8.2. Were correct statistical tests used and assumptions of test not violated? Yes
  8.3. Were statistics reported with levels of significance and/or confidence intervals? Yes
  8.3. Were statistics reported with levels of significance and/or confidence intervals? Yes
  8.4. Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? N/A
  8.4. Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? N/A
  8.5. Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? Yes
  8.5. Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? Yes
  8.6. Was clinical significance as well as statistical significance reported? N/A
  8.6. Was clinical significance as well as statistical significance reported? N/A
  8.7. If negative findings, was a power calculation reported to address type 2 error? N/A
  8.7. If negative findings, was a power calculation reported to address type 2 error? N/A
  9. Are conclusions supported by results with biases and limitations taken into consideration? No
9. Are conclusions supported by results with biases and limitations taken into consideration? No
  9.1. Is there a discussion of findings? Yes
  9.1. Is there a discussion of findings? Yes
  9.2. Are biases and study limitations identified and discussed? No
  9.2. Are biases and study limitations identified and discussed? No
  10. Is bias due to study's funding or sponsorship unlikely? No
10. Is bias due to study's funding or sponsorship unlikely? No
  10.1. Were sources of funding and investigators' affiliations described? No
  10.1. Were sources of funding and investigators' affiliations described? No
  10.2. Was the study free from apparent conflict of interest? No
  10.2. Was the study free from apparent conflict of interest? No